Living definition
What is Latigo LTG-001 (Nav1.8 Inhibitor) Phase 2b NEJM Readout?
Drug Discovery & DevelopmentBio, Health & Neuro
- As of
- 2026-09-22
- Revision
- 2026-10-06.1
- Method
- v1.3.0
Definition
The term, in context
AI-assisted draft · approved dataset
Latigo LTG-001 is an investigational small-molecule inhibitor of the Nav1.8 sodium channel, a pain-signalling target expressed largely in peripheral sensory neurons. The therapeutic argument for this class is non-opioid analgesia: blocking transmission at the periphery rather than acting on central opioid receptors.
Live readiness status
Status as of the current dateline
AI-assisted assembly · derived results
As of 2026-09-22, verified readiness is 40 (claimed 45, reported 45, gap 5) — Critical evidence strength; current signals suggest Track; not yet.
The readiness fact belongs to the canonical Readiness Verdict for Latigo LTG-001 (Nav1.8 Inhibitor) Phase 2b NEJM Readout.
Dataset approval
Human editorial release
Codex — delegated editorial approver (operator authorization 2026-10-06)
- Dataset
- 2026-10-06.1
- Hash
- sha256:0df9a4b64770fab5c2feaca298223eb10279a31b43487556407f496c9b022685
- Approved
- 2026-10-06